BridgeBio Oncology Therapeutics (NASDAQ: BBOT) announced inducement stock-option grants awarded Feb 10, 2026, to two employees hired in January 2026 under its 2025 Inducement Plan.
The awards total 65,350 non-qualified stock options at an exercise price of $10.84 per share, vesting 25% after one year then monthly over 36 months. Grants were approved by the compensation committee under Nasdaq Listing Rule 5635(c)(4).
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – BBOT
-5.15%
16 alerts
-5.15%Session close to close
+7.5%Peak in 2 hr 13 min
$970.26MMarket Cap
0.8xRel. Volume
In the Feb 12 session, BBOT declined 5.15%, reflecting a notable negative market reaction.
Argus tracked a peak move of +7.5% during that session.
Our momentum scanner triggered 16 alerts that day, indicating notable trading interest and price volatility.
The stock moved -5.2% in the session following this news. A negative reaction despite the routine na...
Analysis
The stock moved -5.2% in the session following this news. A negative reaction despite the routine nature of this inducement grant would fit a pattern where non-clinical news sometimes triggers modest downside, as seen with prior events moving -1.25% and -1.95%. The announcement adds incremental stock options but does not change BBOT’s reported liquidity or pipeline data. Given stronger historical responses to clinical updates, any larger decline could reflect broader sentiment or positioning rather than the mechanics of this grant alone.
Key Figures
Current share price:$10.84Inducement option shares:65,350 sharesPar value:$0.0001 per share+3 more
6 metrics
Current share price$10.84Closing price used as exercise price for inducement options
Inducement option shares65,350 sharesAggregate non-qualified stock options granted to new employees
Par value$0.0001 per sharePar value of BBOT common stock underlying inducement options
Initial vesting tranche1/4 of awardVests on first anniversary of employee start date
Monthly vesting period36 monthsEqual monthly installments after first anniversary, subject to service
New hires covered2 employeesInducement awards for individuals hired in January 2026
Late-breaking preclinical data on BBO-10203 as a first-in-class RAS:PI3Kα breaker.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
BBOT has shown positive reactions to clinical data updates, while routine corporate or inducement announcements have produced smaller, mixed price moves.
Recent Company History
Over the last few months, BBOT highlighted several milestones, including preliminary Phase 1 data across three RAS/PI3Kα programs on Jan 7, 2026, which saw a +4.36% move. Multiple prior inducement grants under the 2025 Inducement Plan in December 2025 and January 2026 produced modest, mixed reactions (from -1.95% to +4.6%). Preclinical data on BBO-10203 in December 2025 also coincided with a +2.79% move, underscoring that clinical and preclinical updates have been the more impactful catalysts than hiring-related option grants.
"The employees received, in the aggregate, non-qualified stock options to purchase 65,350 shares"
Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.
inducement grantsfinancial
"today announced it awarded inducement grants on February 10, 2026 under BBOT’s 2025 Inducement Plan"
Inducement grants are special awards of shares or stock options given to new employees to encourage them to join a company or accept a new role. They act like a welcome bonus, providing an extra incentive to attract talent. For investors, these grants can impact a company's costs and share structure, influencing the value of their investments.
nasdaq listing rule 5635(c)(4)regulatory
"as a material inducement to the employees entering into employment with BBOT in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
SOUTH SAN FRANCISCO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded inducement grants on February 10, 2026 under BBOT’s 2025 Inducement Plan as a material inducement to the employment of two individuals hired by BBOT in January 2026.
The employees received, in the aggregate, non-qualified stock options to purchase 65,350 shares of BBOT common stock, par value $0.0001 per share, with an exercise price of $10.84 per share, the closing price of BBOT’s common stock as reported by Nasdaq on the effective date of the grant, which will vest 1/4 on the first anniversary of the employee’s applicable start date and in 36 equal monthly installments thereafter, subject to the employee’s continued service with the Company through each applicable vesting date, or collectively, the Awards.
All of the above-described Awards were granted outside of BBOT’s stockholder-approved equity incentive plans and are pursuant to BBOT’s 2025 Inducement Plan, which was adopted by BBOT’s board of directors in October 2025. The Awards were approved by the compensation committee of the board of directors, which is comprised solely of independent directors, as a material inducement to the employees entering into employment with BBOT in accordance with Nasdaq Listing Rule 5635(c)(4).
About BBOT BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit www.bbotx.com and follow us on LinkedIn.
BBOT Contacts:
Investor Contact: Heather Armstrong, Head of Investor Relations BBOT Investors@BBOTx.com
Media Contact: Jake Robison Inizio Evoke Comms Jake.robison@inizioevoke.com
FAQ
What did BBOT announce about inducement grants on February 11, 2026?
BBOT announced the award of inducement option grants totaling 65,350 shares to two new hires. According to BridgeBio Oncology Therapeutics, the grants were made Feb 10, 2026 under the company’s 2025 Inducement Plan and approved by the compensation committee.
How many options and what exercise price were included in BBOT's inducement awards (BBOT)?
The inducement awards total 65,350 non-qualified stock options with an exercise price of $10.84 per share. According to BridgeBio Oncology Therapeutics, $10.84 equals the Nasdaq closing price on the effective grant date.
What is the vesting schedule for the BBOT inducement stock options?
The options vest 25% after one year, then in 36 equal monthly installments thereafter. According to BridgeBio Oncology Therapeutics, vesting is subject to each employee’s continued service through applicable vesting dates.
Under which plan were BBOT’s inducement awards granted and why?
The awards were granted under BBOT’s 2025 Inducement Plan as material inducements for new employment. According to BridgeBio Oncology Therapeutics, the plan was adopted by the board in October 2025 and used per Nasdaq Listing Rule 5635(c)(4).
Were BBOT’s inducement awards approved by independent directors or a committee?
Yes, the compensation committee approved the awards; the committee comprises solely independent directors. According to BridgeBio Oncology Therapeutics, the committee approved the grants as a material inducement to hire the two employees.
Do BBOT’s inducement grants come from shareholder-approved equity incentive plans?
No, the awards were granted outside the company’s stockholder-approved equity incentive plans. According to BridgeBio Oncology Therapeutics, the grants were made pursuant to the separate 2025 Inducement Plan adopted by the board.
